ClinicalTrials.gg
Sign In
RecruitingNCT07871201Updated Oct 13, 2026

Dynamic Arterial Elastance for Prediction of Vasopressor Requirement After Anesthesia Induction in Elective On-Pump CABG

An observational study in Coronary Artery Disease, sponsored by Elzem SEN. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Elzem SEN · Observational

Updated Oct 13, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
42
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to determine whether dynamic arterial elastance (EaDyn), measured after anesthesia induction, can predict the need for vasopressor treatment in patients undergoing elective on-pump coronary artery bypass graft surgery. EaDyn will be calculated from pulse pressure variation and stroke volume variation. Hemodynamic measurements will be recorded before anesthesia induction and at 1, 3, and 5 minutes after induction. The study is prospective and observational, and no additional intervention will be performed as part of the study.

02

Conditions studied

  • Coronary Artery Disease

Keywords

  • Dynamic Arterial Elastance
  • EaDyn
  • Vasopressor Requirement
  • Coronary Artery Bypass Greft
  • CABG
  • Anesthesia Induction
  • Pulse Pressure Variation
  • Stroke Volume Variation
03

In context

Coronary Artery Disease

5,676 studies on the registry are indexed under Coronary Artery Disease; 958 are open to participants now.

This study's planned enrollment of 42 is below the median of 335 across 1,978 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Elzem SEN is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18-80 years undergoing elective on-pump coronary artery bypass graft surgery at Gaziantep University Hospital who meet the predefined inclusion and exclusion criteria. Patients will undergo routine anesthesia and surgical management. Hemodynamic parameters will be recorded before anesthesia induction and at 1, 3, and 5 minutes after induction, and vasopressor use will be documented.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Patients undergoing elective cardiac surgery with cardiopulmonary bypass (on-pump).
  3. Patients with arterial catheter monitoring.
  4. Patients receiving mechanical ventilation.

Exclusion criteria

Exclusion Criteria:

  1. Arrhythmia (e.g., atrial fibrillation).
  2. Severe aortic regurgitation.
  3. Spontaneous breathing.
  4. Low tidal volume.
  5. Emergency surgery.
  6. Off-pump cardiac surgery (cardiac surgery performed without cardiopulmonary bypass).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
42 participants (estimated)
Patient registry
No

Groups and cohorts

  • Elective On-Pump CABG Cohort

    Adults aged 18-80 years undergoing elective on-pump coronary artery bypass graft surgery who meet the study eligibility criteria. Hemodynamic parameters will be recorded before and after anesthesia induction, and vasopressor use will be documented.

    Other: No intervention

Interventions

  • OtherNo intervention

    This is an observational study. No study-specific intervention is assigned to participants. Anesthesia and surgical management will be performed according to routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Vasopressor Requirement Within 5 Minutes After Anesthesia Induction

    Requirement for administration of any vasopressor after anesthesia induction, recorded as a binary outcome (yes/no). Vasopressor use will be assessed during the post-induction hemodynamic assessment period.

    Time frame: From anesthesia induction to 5 minutes after induction

07

Study locations

1 of 1 sites recruiting
  • Gaziantep University Hospital
    Gaziantep, Turkey (Türkiye)
    • ELZEM ŞEN, MD · Contact · drelzemsen@gmail.com · +905327842151
    • ELZEM ŞEN, MD · Principal investigator
    • ZEYNEP AKGÖBEK, MD · Sub investigator
    Recruiting
08

References and documents

Publications

  • Bar S, Nguyen M, Abou-Arab O, Dupont H, Bouhemad B, Guinot PG. Dynamic Arterial Elastance Is Associated With the Vascular Waterfall in Patients Treated With Norepinephrine: An Observational Study. Front Physiol. 2021 May 4;12:583370. doi: 10.3389/fphys.2021.583370. eCollection 2021. PubMed 34017263 ↗
  • Zhou X, Pan W, Chen B, Xu Z, Pan J. Predictive performance of dynamic arterial elastance for arterial pressure response to fluid expansion in mechanically ventilated hypotensive adults: a systematic review and meta-analysis of observational studies. Ann Intensive Care. 2021 Jul 31;11(1):119. doi: 10.1186/s13613-021-00909-2. PubMed 34331607 ↗
  • Garcia MI, Romero MG, Cano AG, Aya HD, Rhodes A, Grounds RM, Cecconi M. Dynamic arterial elastance as a predictor of arterial pressure response to fluid administration: a validation study. Crit Care. 2014 Nov 19;18(6):626. doi: 10.1186/s13054-014-0626-6. PubMed 25407570 ↗
  • Monge Garcia MI, Gil Cano A, Gracia Romero M. Dynamic arterial elastance to predict arterial pressure response to volume loading in preload-dependent patients. Crit Care. 2011;15(1):R15. doi: 10.1186/cc9420. Epub 2011 Jan 12. PubMed 21226909 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers. No plan has been established for sharing individual-level participant data beyond the research team. Study results will be reported in aggregate form.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.

Of 726 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 6 months is below that.

Counting every sponsor, half of 857 studies reached it within 43 months; a quarter within 22 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 13, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07871201
Lead sponsor
Elzem SEN
Responsible party
Elzem SEN (Associate Professor, University of Gaziantep) — Sponsor-investigator
First posted
Oct 13, 2026
Start date
Oct 1, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

ELZEM ŞEN, MD
Contact
drelzemsen@gmail.com
+905327842151
ELZEM ŞEN, MD
study chair · University of Gaziantep

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Coronary Artery Disease →

Other studies from this sponsor

Elzem SEN

Start the discussion